Overview
The aim of this study is to offer patients two treatment options: morning or evening administration of a JAK inhibitor prescribed within the framework of its marketing authorization, according to the EULAR response.
The objective is to determine whether evening administration in our patients with rheumatoid arthritis provides greater efficacy than morning administration in our patients taking JAK inhibitors once daily.
Eligibility
Inclusion Criteria:
- Patient aged over 18 years
- Patient with Rheumatoid Arthritis according to the 2010 ACR/EULAR criteria
- Patient meeting the criteria for initiation of a JAK inhibitor according to the marketing authorization and international recommendations
- Patient capable of providing informed, written, dated, and signed consent before the start of any trial-related procedure.
Exclusion Criteria:
- No contraindication to a bDMARD
- Not stable dose of corticosteroids in the 4 weeks preceding enrollment
- Not stable dose of maintenance therapy (methotrexate, leflunomide, hydroxychloroquine, cyclosporine, gold salts) in the 4 weeks preceding enrollment
- Prior treatment with a JAK inhibitor
- Patient unable to be followed-up in the study during 6 months
- Minors or adults under guardianship or curatorship, or deprived of their liberty
- Pregnant or breastfeeding patient
- Patient refusing to use an effective method of contraception for the duration of the study
- Person not affiliated with a social security scheme.
